Hidradenitis Suppurativa (Hurley Stage I-II)
Not recommended: the only published report of leech therapy in hidradenitis suppurativa describes a harmful outcome.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for hidradenitis suppurativa (HS). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for HS is investigational.
- What evidence exists?
- Tier C (investigational). No study showing benefit of leech therapy in hidradenitis suppurativa was identified; the only published report found (Ferhatoglu 2026) describes harm — a foreign-body granuloma with lymphedema after leech therapy. There are no randomized controlled trials. Evidence-based therapy includes topical clindamycin, oral antibiotics (tetracyclines, clindamycin-rifampicin), adalimumab (FDA-approved for moderate-to-severe HS), secukinumab (newly approved), hormonal therapy, and surgical excision (deroofing, wide excision) for refractory disease. Leech application on active draining lesions is dangerous.
- Main risks
- Dangerous infection spread if leeches are applied on or near actively draining lesions
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness in the axilla, groin, or other intertriginous areas for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection (amplified in HS-prone skin)
- Allergic reaction to leech saliva (uncommon)
- Triggering a new HS flare at the bite site
- Small permanent scars in already scar-prone tissue
- Delay or replacement of evidence-based biologic or antibiotic therapy
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Who should not consider this
- Patients with any active draining lesion, abscess, or sinus tract
- Patients with Hurley stage III disease (extensive sinus tract formation)
- Patients on immunosuppression with neutropenia (TNF inhibitors, methotrexate)
- Patients on anticoagulants, with hemophilia, or with anemia
- Patients with poorly controlled diabetes (higher infection risk)
- Patients who have not been evaluated by dermatology for biologic eligibility
- People with an active infection at the planned application site
- Patients who are pregnant (leech therapy is not done during pregnancy) or breastfeeding (discuss it with your doctor)
- What to ask your clinician
- What is my Hurley stage and HiSCR score, and have I been seen by an HS specialist?
- Have I tried first-line topical clindamycin, tetracyclines, or clindamycin-rifampicin combination?
- Am I a candidate for adalimumab or secukinumab? Have I been screened for biologic therapy?
- Have I been counseled on weight management, smoking cessation, and modifiable risk factors?
- Am I a candidate for surgical deroofing or wide excision of recalcitrant lesions?
- What evidence supports leech therapy in HS specifically?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What scarring risk does this add to skin that may already scar abnormally?
- When to seek urgent care
- Spreading redness, severe pain, fever, or pus drainage (worsening infection)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills (possible bacteremia)
- Hardness, dark discoloration, or crepitus in the affected area (necrotizing infection)
- Hives, throat tightness, or breathing difficulty
- Mental status changes or rapid heart rate (possible sepsis)
- Bleeding from a bite site that soaks through more than one dressing per hour
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Difficulty moving the affected area (axilla, groin) due to severe pain or swelling
What this does NOT mean
- This is not FDA-cleared for hidradenitis suppurativa.
- There is no evidence of efficacy on flare reduction versus proven biologics or antibiotics; the only published report is a single case of harm.
- Mechanism rationale (local immunomodulation) does NOT establish clinical efficacy.
- Leech therapy is NEVER applied on active draining lesions — that risks dangerous infection spread.
- Leech therapy is not a substitute for biologic therapy, antibiotics, or surgical management when indicated.
- It does not prevent progression to Hurley Stage III.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- L73.2
- Safety tier
- High
Evidence Summary
No controlled clinical trial or case series demonstrating benefit of leech therapy in hidradenitis suppurativa was identified in PubMed or Europe PMC; the only published report found (Ferhatoglu et al., Dermatol Online J 2026, PMID 42246321, a case-report letter) documents harm — a foreign-body granuloma complicated by lymphedema following leech therapy in an HS patient. Given this documented adverse-event signal and the infection risk inherent to HS lesions, leech therapy is not recommended, and any exploratory use would be investigational only, never on actively draining lesions. Standard management (topical clindamycin, oral antibiotics, adalimumab for moderate-severe disease, surgical excision for severe disease) remains primary.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active draining lesions or abscess
- Hurley stage III with extensive sinus tract disease
- Active immunomodulator-induced immunosuppression with neutropenia
- Concurrent TNF-alpha inhibitor with infection risk
- MRSA colonization with recent superinfection
- Diabetic foot syndrome or peripheral neuropathy
Related Conditions
Chronic Recurrent Cellulitis
Investigational use for chronic recurrent (non-acute) cellulitis with underlying lymphedema or venous insufficiency.
Plaque Psoriasis (Localized)
Investigational adjunct, not a primary treatment; a few small, mostly uncontrolled studies report lower PASI scores.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; no study in this condition was identified, only small series in venous ulcer and varicose disease.